Antibodies Targeting Human or Mouse VSIG4 Repolarize Tumor-Associated Macrophages Providing the Potential of Potent and Specific Clinical Anti-Tumor Response Induced across Multiple Cancer Types

• Published in: International journal of molecular sciences Vol. 25; no. 11; p. 6160
• Main Authors: Sazinsky, Stephen, Zafari, Mohammad, Klebanov, Boris, Ritter, Jessica, Nguyen, Phuong A, Phennicie, Ryan T, Wahle, Joe, Kauffman, Kevin J, Razlog, Maja, Manfra, Denise, Feldman, Igor, Novobrantseva, Tatiana
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.06.2024; MDPI
• Subjects: Amino acids; Animals; Antibodies; Cancer; Cell Line, Tumor; Chemokines; Cytokines; Cytokines - metabolism; Datasets; Female; Humans; immunotherapy; Kinases; Lung cancer; Lymphocyte Activation - immunology; Lymphocytes; macrophage; Macrophages; Medical prognosis; Mice; Mice, Inbred C57BL; Monoclonal antibodies; Neoplasms - immunology; Neoplasms - metabolism; Ovarian cancer; Phosphorylation; Proteins; Receptors, Complement; Scientific equipment and supplies industry; Smallwood, DeAnn; T cells; Tumor-Associated Macrophages - immunology; Tumor-Associated Macrophages - metabolism; Tumors; Viral antibodies; VSIG4; United States; California; macrophage; immunotherapy; VSIG4
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25116160

V-set immunoglobulin domain-containing 4 (VSIG4) is a B7 family protein with known roles as a C3 fragment complement receptor involved in pathogen clearance and a negative regulator of T cell activation by an undetermined mechanism. VSIG4 expression is specific for tumor-associated and select tissue-resident macrophages. Increased expression of VSIG4 has been associated with worse survival in multiple cancer indications. Based upon computational analysis of transcript data across thousands of tumor and normal tissue samples, we hypothesized that VSIG4 has an important role in promoting M2-like immune suppressive macrophages and that targeting VSIG4 could relieve VSIG4-mediated macrophage suppression by repolarizing tumor-associated macrophages (TAMs) to an inflammatory phenotype. We have also observed a cancer-specific pattern of VSIG4 isoform distribution, implying a change in the functional regulation in cancer. Through a series of in vitro, in vivo, and ex vivo assays we demonstrate that anti-VSIG4 antibodies repolarize M2 macrophages and induce an immune response culminating in T cell activation. Anti-VSIG4 antibodies induce pro-inflammatory cytokines in M-CSF plus IL-10-driven human monocyte-derived M2c macrophages. Across patient-derived tumor samples from multiple tumor types, anti-VSIG4 treatment resulted in the upregulation of cytokines associated with TAM repolarization and T cell activation and chemokines involved in immune cell recruitment. VSIG4 blockade is also efficacious in a syngeneic mouse model as monotherapy as it enhances efficacy in combination with anti-PD-1, and the effect is dependent on the systemic availability of CD8 T cells. Thus, VSIG4 represents a promising new target capable of triggering an anti-cancer response via multiple key immune mechanisms.